Esophageal Cancer – Pipeline Review, H1 2012

Introduction

Global Markets Direct’s, 'Esophageal Cancer - Pipeline Review, H1 2012', provides an overview of the Esophageal Cancer therapeutic pipeline. This report provides information on the therapeutic development for Esophageal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Esophageal Cancer. 'Esophageal Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Esophageal Cancer.
- A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Esophageal Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Highlights

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Esophageal Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Esophageal Cancer pipeline depth and focus of Esophageal Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
[Studien Infos ausblenden]

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Esophageal Cancer Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Esophageal Cancer 12
Esophageal Cancer Therapeutics under Development by Companies 14
Esophageal Cancer Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 27
Comparative Analysis 27
Mid Clinical Stage Products 28
Comparative Analysis 28
Early Clinical Stage Products 29
Comparative Analysis 29
Discovery and Pre-Clinical Stage Products 30
Comparative Analysis 30
Esophageal Cancer Therapeutics – Products under Development by Companies 31
Esophageal Cancer Therapeutics – Products under Investigation by Universities/Institutes 33
Companies Involved in Esophageal Cancer Therapeutics Development 52
Bristol-Myers Squibb Company 52
Shionogi & Co., Ltd. 53
Eli Lilly and Company 54
GlaxoSmithKline plc 55
Tekmira Pharmaceuticals Corp. 56
Daiichi Sankyo Company, Ltd 57
YM BioSciences Inc. 58
Novartis AG 59
Aphios Corporation 60
Cell Therapeutics, Inc. 61
Celldex Therapeutics, Inc. 62
Proteo, Inc. 63
GANYMED Pharmaceuticals AG 64
Ascenta Therapeutics, Inc. 65
Merrimack Pharmaceuticals, Inc. 66
Omeros Corporation 67
PharmaMar, S.A. 68
ImmunoFrontier, Inc. 69
Mebiopharm Co., Ltd. 70
Eurofarma 71
Biotech Pharmaceuticals Co., Ltd. 72
Esophageal Cancer – Therapeutics Assessment 73
Assessment by Monotherapy Products 73
Assessment by Combination Products 74
Assessment by Route of Administration 75
Assessment by Molecule Type 77
Drug Profiles 80
Tykerb + Capecitabine + Oxaliplatin - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 81
Cisplatin + Capecitabine + Cetuximab + Radiation Therapy - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 83
Cisplatin + Capecitabine + Radiation Therapy - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 85
Paclitaxel + Cisplatin + Cetuximab + Radiation Therapy - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 87
Cetuximab + Cisplatin + Docetaxel + Radiation Therapy - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Fluorouracil + Cisplatin + Radiation Therapy - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Cisplatin + Capecitabine + Cetuximab + Radiation Therapy - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Fluorouracil + Cisplatin + Epirubicin + Radiation Therapy - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Cisplatin + Epirubicin + Fluorouracil - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
TheraCIM - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Esomeprazole + Aspirin - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Lobaplatin + 5-Fluorouracil + Leucovorin - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Iressa - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
Docetaxel + Nedaplatin - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
Irinotecan Hydrochloride Trihydrate + Cisplatin - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 107
Cisplatin + 5-Fluorouracil + Radical radiotherapy - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 109
Cisplatinum + Fluorouracil - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
Oxaliplatin + Leucovorin calcium + Fluorouracil + Radiation Therapy - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 112
Epirubicin + Oxaliplatin + Capecitabine - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 114
Cisplatin + Fluorouracil - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
Esomeprazole - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
Navelbine + Cisplatin + Radiotherapy - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
Trastuzumab + Carboplatin + Paclitaxel + Radiation Therapy - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 120
Nimotuzumab + Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
FOLFOX 4 + Radiation Therapy - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
Esophageal Cancer Therapeutics – Drug Profile Updates 125
Esophageal Cancer Therapeutics – Discontinued Products 126
Esophageal Cancer Therapeutics - Dormant Products 129
Esophageal Cancer – Product Development Milestones 140
Featured News & Press Releases 140
Aug 09, 2011: Tekmira Announces Additional Clinical Trial Of TKM-PLK1 With US National Cancer Institute 140
Feb 23, 2011: CTI Announces Publication Of Phase II Study Results Of OPAXIO In American Journal Of Clinical Oncology 141
Jul 07, 2010: OPAXIO Phase II Study Results Confirm High Rate Of Complete Response With Low Rate Of Side Effects In Patients With Advanced Esophageal Cancer 141
Apr 22, 2010: Genentech Submits Supplemental Application To FDA For Herceptin In Advanced HER2-Positive Stomach Cancer 142
Feb 04, 2010: Proteo, Inc./Proteo Biotech AG: Orphan Drug Designation For Elafin In The Treatment Of Oesophagus Carcinoma 143
Nov 16, 2009: Proteo, Inc./Proteo Biotech AG: European Medicines Agency EMEA Recommends Orphan Drug Status For Elafin In The Treatment Of Esophagus Carcinoma 143
Sep 14, 2009: Celldex Therapeutics Announces Dosing Of First Patient In Phase I/II Clinical Trial Of CDX-1401 143
Jun 03, 2009: Paclitaxel Poliglumex (OPAXIO) Added To Cisplatin And Radiation Produces 45% Pathologic Complete Remissions In Patients With Esophageal Cancer 144
Feb 02, 2009: Shionogi announces it has entered into a licensing agreement on Peptide vaccines for cancer treatment with OncoTherapy Science, Inc. 145
Sep 24, 2008: OPAXIO Phase II Trial In Esophageal Cancer To Be Presented In Proffered Session At The International Society Of Gastrointestinal Oncology Annual Meeting 145
Appendix 146
Methodology 146
Coverage 146
Secondary Research 146
Primary Research 146
Expert Panel Validation 147
Contact Us 147
Disclaimer 147
[Inhaltsverzeichnis ausblenden]

List of Tables
Number of Products Under Development for Esophageal Cancer, H1 2012 12
Products under Development for Esophageal Cancer – Comparative Analysis, H1 2012 13
Number of Products under Development by Companies, H1 2012 15
Number of Products under Development by Companies, H1 2012 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2012 18
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 19
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 21
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 22
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 23
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 24
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 25
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 26
Comparative Analysis by Late Stage Development, H1 2012 27
Comparative Analysis by Mid Clinical Stage Development, H1 2012 28
Comparative Analysis by Early Clinical Stage Development, H1 2012 29
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 30
Products under Development by Companies, H1 2012 31
Products under Development by Companies, H1 2012 (Contd..1) 32
Products under Investigation by Universities/Institutes, H1 2012 33
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 34
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 35
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 36
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 37
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 38
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 39
Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 40
Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 41
Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 42
Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 43
Products under Investigation by Universities/Institutes, H1 2012 (Contd..11) 44
Products under Investigation by Universities/Institutes, H1 2012 (Contd..12) 45
Products under Investigation by Universities/Institutes, H1 2012 (Contd..13) 46
Products under Investigation by Universities/Institutes, H1 2012 (Contd..14) 47
Products under Investigation by Universities/Institutes, H1 2012 (Contd..15) 48
Products under Investigation by Universities/Institutes, H1 2012 (Contd..16) 49
Products under Investigation by Universities/Institutes, H1 2012 (Contd..17) 50
Products under Investigation by Universities/Institutes, H1 2012 (Contd..18) 51
Bristol-Myers Squibb Company, H1 2012 52
Shionogi & Co., Ltd., H1 2012 53
Eli Lilly and Company, H1 2012 54
GlaxoSmithKline plc, H1 2012 55
Tekmira Pharmaceuticals Corp., H1 2012 56
Daiichi Sankyo Company, Ltd, H1 2012 57
YM BioSciences Inc., H1 2012 58
Novartis AG, H1 2012 59
Aphios Corporation, H1 2012 60
Cell Therapeutics, Inc., H1 2012 61
Celldex Therapeutics, Inc., H1 2012 62
Proteo, Inc., H1 2012 63
GANYMED Pharmaceuticals AG, H1 2012 64
Ascenta Therapeutics, Inc., H1 2012 65
Merrimack Pharmaceuticals, Inc., H1 2012 66
Omeros Corporation, H1 2012 67
PharmaMar, S.A., H1 2012 68
ImmunoFrontier, Inc., H1 2012 69
Mebiopharm Co., Ltd., H1 2012 70
Eurofarma, H1 2012 71
Biotech Pharmaceuticals Co., Ltd., H1 2012 72
Assessment by Monotherapy Products, H1 2012 73
Assessment by Combination Products, H1 2012 74
Assessment by Stage and Route of Administration, H1 2012 76
Assessment by Molecule Type, H1 2012 79
Esophageal Cancer Therapeutics – Drug Profile Updates 125
Esophageal Cancer Therapeutics – Discontinued Products 126
Esophageal Cancer Therapeutics – Discontinued Products (Contd..1) 127
Esophageal Cancer Therapeutics – Discontinued Products (Contd..2) 128
Esophageal Cancer Therapeutics – Dormant Products 129
Esophageal Cancer Therapeutics – Dormant Products (Contd..1) 130
Esophageal Cancer Therapeutics – Dormant Products (Contd..2) 131
Esophageal Cancer Therapeutics – Dormant Products (Contd..3) 132
Esophageal Cancer Therapeutics – Dormant Products (Contd..4) 133
Esophageal Cancer Therapeutics – Dormant Products (Contd..5) 134
Esophageal Cancer Therapeutics – Dormant Products (Contd..6) 135
Esophageal Cancer Therapeutics – Dormant Products (Contd..7) 136
Esophageal Cancer Therapeutics – Dormant Products (Contd..8) 137
Esophageal Cancer Therapeutics – Dormant Products (Contd..9) 138
Esophageal Cancer Therapeutics – Dormant Products (Contd..10) 139
List of Figures
Number of Products under Development for Esophageal Cancer, H1 2012 12
Products under Development for Esophageal Cancer – Comparative Analysis, H1 2012 13
Products under Development by Companies, H1 2012 14
Products under Investigation by Universities/Institutes, H1 2012 17
Late Stage Products, H1 2012 27
Mid Clinical Stage Products, H1 2012 28
Early Clinical Stage Products, H1 2012 29
Discovery and Pre-Clinical Stage Products, H1 2012 30
Assessment by Monotherapy Products, H1 2012 73
Assessment by Combination Products, H1 2012 74
Assessment by Route of Administration, H1 2012 75
Assessment by Stage and Route of Administration, H1 2012 76
Assessment by Molecule Type, H1 2012 77
Assessment by Stage and Molecule Type, H1 2012 78
[Tabellenverzeichnis ausblenden]